Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 15/20 | 0.53 |
| ▸ | OPRM1 | P35372 | 10/20 | 0.53 |
| ▸ | OPRK1 | P41145 | 5/20 | 0.53 |
| ▸ | TFPI | P10646 | 1/20 | 0.52 |
| ▸ | CCKBR | P32239 | 4/20 | 0.52 |
| ▸ | CCKAR | P32238 | 3/20 | 0.52 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.49 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29375967 | 0.89 | TFPI (0.59) | OPRD1OPRM1OPRK1TFPINPBWR1 | |
| SCHEMBL29663833 | 0.89 | OPRD1 (0.53) | OPRD1OPRM1OPRK1TFPICCKBR | |
| SCHEMBL29376413 | 0.89 | TFPI (0.56) | OPRD1OPRM1OPRK1TFPINPBWR1 | |
| SCHEMBL31433273 | 0.89 | BACE1 (0.59) | — | |
| SCHEMBL30721576 | 0.88 | TFPI (0.61) | OPRD1OPRM1OPRK1TFPINPBWR1 | |
| SCHEMBL29590452 | 0.88 | OPRM1 (0.55) | OPRD1OPRM1OPRK1TFPI | |
| SCHEMBL31480024 | 0.87 | OPRL1 (0.63) | OPRD1OPRM1OPRK1TFPIOPRL1 | |
| SCHEMBL30343582 | 0.87 | NPY4R (0.55) | OPRD1 | |
| SCHEMBL29767368 | 0.87 | NPY4R (0.55) | OPRD1 | |
| Acetic Acid SCHEMBL29981808 | 0.87 | LNPEP (0.53) | OPRD1OPRM1OPRK1CCKBRCCKAR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12564579-B2 | Topical formulations of (1S)-1-phenyl-2-pyridin-2-ylethanamine | BIOHAVEN THERAPEUTICS LTD. (VG) | 2026-03-03 | — | — | US | disclosed |
| US-20230190719-A1 | TOPICAL FORMULATIONS OF (1S)-1-PHENYL-2-PYRIDIN-2-YLETHANAMINE | BIOHAVEN THERAPEUTICS LTD (US) | 2023-06-22 | — | — | US | disclosed |
| EP-4168116-A1 | TOPICAL FORMULATIONS OF (1S)-1-PHENYL-2-PYRIDIN-2-YLETHANAMINE | Biohaven Therapeutics Ltd. (US) | 2023-04-26 | — | — | EP | disclosed |
| CN-115836052-A | Topical formulations of (1S) -1-phenyl-2-pyridin-2-ylethylamine | 拜尔哈文制药股份有限公司 | 2023-03-21 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12564579-B2 | Topical formulations of (1S)-1-phenyl-2-pyridin-2-ylethanamine | CERS2, CNR2, FAAH2 | OPRD1 696/4885OPRM1 507/4885OPRK1 1115/4885 |
| US-20230190719-A1 | TOPICAL FORMULATIONS OF (1S)-1-PHENYL-2-PYRIDIN-2-YLETHANAMINE | TRPV1, PNN, SLC18A2 | OPRD1 51/4885OPRM1 99/4885OPRK1 49/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.